Computational Investigations on the Natural Small Molecule as an Inhibitor of Programmed Death Ligand 1 for Cancer Immunotherapy

Several therapeutic monoclonal antibodies approved by the FDA are available against the PD-1/PD-L1 (programmed death 1/programmed death ligand 1) immune checkpoint axis, which has been an unprecedented success in cancer treatment. However, existing therapeutics against PD-L1, including small molecul...

Deskribapen osoa

Xehetasun bibliografikoak

Egile Nagusiak:	Geethu S Kumar, Mahmoud Moustafa, Amaresh Kumar Sahoo, Petr Malý, Shiv Bharadwaj
Formatua:	Artigo
Hizkuntza:	Inglês
Argitaratua:	MDPI AG 2022-04-01
Saila:	Life
Gaiak:	programmed death ligand 1 natural products immunotherapy Neoenactin B1 molecular dynamics simulation
Sarrera elektronikoa:	https://www.mdpi.com/2075-1729/12/5/659
Etiketak:	Etiketa erantsi Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!